Additionally, glucagon-like peptide-1 receptor agonists (GLP-1RAs), which is another class of antidiabetic drug currently under evaluation for NAFLD, has been shown bone-protective effects, probably through the activation of GLP-1R/MAPK signaling pathway, GLP-1R/PI3K/AKT signaling pathway and Wnt/β-catenin pathway. This evidence concerns the gene AKT1 and metabolic dysfunction-associated steatotic liver disease.